BOSTON--(BUSINESS WIRE)--Feb. 22, 2006--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced preliminary results of its randomized, blinded, controlled, phase 2 clinical trial of CRx-140 in patients with psoriasis. Statistical significance of the primary and secondary efficacy endpoints of reduction in PGA and PASI versus active control was not achieved. CRx-140 was generally well tolerated. These results, taken within the context of the CombinatoRx portfolio of product candidates, are not supportive of further clinical evaluation of CRx-140 as an oral, systemic product candidate for psoriasis.
